##gff-version 3
##sequence-region Q14563 1 771
Q14563	UniProtKB	Signal peptide	1	20	.	.	.	Ontology_term=ECO:0000255;evidence=ECO:0000255	
Q14563	UniProtKB	Chain	21	771	.	.	.	ID=PRO_0000032303;Note=Semaphorin-3A	
Q14563	UniProtKB	Domain	31	514	.	.	.	Note=Sema;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00352	
Q14563	UniProtKB	Domain	580	664	.	.	.	Note=Ig-like C2-type	
Q14563	UniProtKB	Compositional bias	727	769	.	.	.	Note=Arg/Lys-rich (basic)	
Q14563	UniProtKB	Glycosylation	53	53	.	.	.	Note=N-linked (GlcNAc...) asparagine;Ontology_term=ECO:0000255;evidence=ECO:0000255	
Q14563	UniProtKB	Glycosylation	125	125	.	.	.	Note=N-linked (GlcNAc...) asparagine;Ontology_term=ECO:0000255;evidence=ECO:0000255	
Q14563	UniProtKB	Glycosylation	590	590	.	.	.	Note=N-linked (GlcNAc...) asparagine;Ontology_term=ECO:0000255;evidence=ECO:0000255	
Q14563	UniProtKB	Disulfide bond	103	114	.	.	.	Ontology_term=ECO:0000250;evidence=ECO:0000250	
Q14563	UniProtKB	Disulfide bond	132	141	.	.	.	Ontology_term=ECO:0000250;evidence=ECO:0000250	
Q14563	UniProtKB	Disulfide bond	269	381	.	.	.	Ontology_term=ECO:0000250;evidence=ECO:0000250	
Q14563	UniProtKB	Disulfide bond	293	341	.	.	.	Ontology_term=ECO:0000250;evidence=ECO:0000250	
Q14563	UniProtKB	Disulfide bond	517	535	.	.	.	Ontology_term=ECO:0000250;evidence=ECO:0000250	
Q14563	UniProtKB	Disulfide bond	649	722	.	.	.	Ontology_term=ECO:0000250;evidence=ECO:0000250	
Q14563	UniProtKB	Natural variant	66	66	.	.	.	ID=VAR_069200;Note=In HH16%3B phenotype consistent with Kallmann syndrome. R->W;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:22927827,ECO:0000269|PubMed:25077900;Dbxref=dbSNP:rs199979628,PMID:22927827,PMID:25077900	
Q14563	UniProtKB	Natural variant	82	82	.	.	.	ID=VAR_072986;Note=In HH16%3B unknown pathological significance. L->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:25077900;Dbxref=PMID:25077900	
Q14563	UniProtKB	Natural variant	131	131	.	.	.	ID=VAR_036283;Note=In a breast cancer sample%3B somatic mutation. A->T;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:16959974;Dbxref=dbSNP:rs143007146,PMID:16959974	
Q14563	UniProtKB	Natural variant	153	153	.	.	.	ID=VAR_069201;Note=In HH16%3B phenotype consistent with Kallmann syndrome. N->S;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:22927827,ECO:0000269|PubMed:25077900;Dbxref=dbSNP:rs139295139,PMID:22927827,PMID:25077900	
Q14563	UniProtKB	Natural variant	342	342	.	.	.	ID=VAR_072987;Note=In HH16%3B phenotype consistent with Kallmann syndrome. M->T;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:25077900;Dbxref=PMID:25077900	
Q14563	UniProtKB	Natural variant	396	396	.	.	.	ID=VAR_064749;Note=Found in a renal cell carcinoma sample%3B somatic mutation. P->S;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:21248752;Dbxref=dbSNP:rs866354226,PMID:21248752	
Q14563	UniProtKB	Natural variant	400	400	.	.	.	ID=VAR_069202;Note=In HH16%3B phenotype consistent with Kallmann syndrome%3B digenic%3B found in a patient also carrying mutation Cys-268 in PROKR2. I->V;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:22927827;Dbxref=dbSNP:rs36026860,PMID:22927827	
Q14563	UniProtKB	Natural variant	435	435	.	.	.	ID=VAR_069203;Note=In HH16%3B phenotype consistent with Kallmann syndrome%3B digenic%3B found in patients also carrying mutation Cys-268 in PROKR2 or mutation Arg-687 in FGFR1. V->I;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:22927827,ECO:0000269|PubMed:25077900;Dbxref=dbSNP:rs147436181,PMID:22927827,PMID:25077900	
Q14563	UniProtKB	Natural variant	447	447	.	.	.	ID=VAR_072988;Note=In HH16%3B phenotype consistent with Kallmann syndrome. D->G;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:25077900;Dbxref=dbSNP:rs761486957,PMID:25077900	
Q14563	UniProtKB	Natural variant	484	484	.	.	.	ID=VAR_072989;Note=In HH16%3B unknown pathological significance. R->W;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:25077900;Dbxref=dbSNP:rs137871935,PMID:25077900	
Q14563	UniProtKB	Natural variant	657	657	.	.	.	ID=VAR_072990;Note=In HH16%3B phenotype consistent with Kallmann syndrome. I->M;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:25077900;Dbxref=dbSNP:rs748219597,PMID:25077900	
Q14563	UniProtKB	Natural variant	688	688	.	.	.	ID=VAR_069204;Note=In HH16%3B phenotype consistent with Kallmann syndrome%3B digenic%3B found in a patient also carrying mutation Asp-217 in KAL1. T->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:22927827;Dbxref=dbSNP:rs318240751,PMID:22927827	
Q14563	UniProtKB	Natural variant	730	730	.	.	.	ID=VAR_069205;Note=In HH16%3B phenotype consistent with Kallmann syndrome. R->Q;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:22927827,ECO:0000269|PubMed:25077900;Dbxref=dbSNP:rs318240752,PMID:22927827,PMID:25077900	
Q14563	UniProtKB	Natural variant	733	733	.	.	.	ID=VAR_069206;Note=In HH16%3B phenotype consistent with Kallmann syndrome. R->H;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:22927827;Dbxref=dbSNP:rs318240753,PMID:22927827	
